Stock MVIR B MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

News Medivir AB

Equities

MVIR B

SE0020181014

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:32 2024-05-03 am EDT 		5-day change 1st Jan Change
3.05 SEK -3.79% Intraday chart for Medivir AB -5.86% +7.02%
Apr. 30 Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024
Apr. 30 Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioStock: Double thumbs up for Medivir from the FDA
AQ
Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
AQ
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Medivir brings the Q1 webcast forward to 10 a.m. on April 30
AQ
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
AQ
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima
CI
BioStock: Medivir optimizes study design after meeting FDA
AQ
Medivir Gets Two US FDA Designations for MIV-711
MT
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
PU
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
AQ
FDA Grants Medivir AB´S MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Legg-Calvé-Perthes Disease
CI
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
AQ
BioStock: Medivir's partner makes clinical progress in veterinary project
AQ
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act
PU
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
AQ
BioStock: Medivir continues to accelerate development with fostrox
AQ
Medivir : The Nomination Committees proposal for the AGM
PU
Medivir to present at Investing in Oncology Forum on April 10
AQ
Medivir : Corporate Governance Report
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. News Medivir AB